These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 30790013)

  • 1. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
    Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
    Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
    Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
    Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
    Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.